Quick Answer
Sagimet Biosciences Inc. reported Earnings Per Share Diluted of $1.58 (loss) per share for the year ending 2025.
- Sagimet Biosciences Inc. showed a decrease of -9.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Sagimet Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $38.37 (loss) per share | Q3 2022: $40.34 (loss) per share | Q1 2023: $35.58 (loss) per share | Q2 2023: $35.80 (loss) per share | Q3 2023: $0.35 (loss) per share | Q1 2024: $0.23 (loss) per share | Q2 2024: $0.25 (loss) per share | Q3 2024: $0.45 (loss) per share | Q1 2025: $0.56 (loss) per share | Q2 2025: $0.32 (loss) per share | Q3 2025: $0.40 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), Sagimet Biosciences Inc.'s Earnings Per Share Diluted has grown by 99.0%.
- Historical annual values: Fiscal year 2025: $1.58 (loss) per share | Fiscal year 2024: $1.45 (loss) per share | Fiscal year 2023: $2.66 (loss) per share | Fiscal year 2022: $165.20 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: